Several other research analysts also recently commented on OBSV. Wedbush set a $34.00 price target on shares of Obseva and gave the stock a “buy” rating in a research note on Friday, January 25th. HC Wainwright reissued a “buy” rating on shares of Obseva in a research note on Monday, April 29th. Zacks Investment Research downgraded shares of Obseva from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Finally, TheStreet cut shares of Obseva from a “c-” rating to a “d+” rating in a report on Wednesday, January 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $29.14.
NASDAQ:OBSV traded down $0.04 on Wednesday, reaching $12.55. 35,799 shares of the company’s stock were exchanged, compared to its average volume of 32,575. The company has a quick ratio of 6.73, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $573.47 million, a PE ratio of -6.57 and a beta of 1.16. Obseva has a 52 week low of $10.23 and a 52 week high of $20.35.
Several institutional investors and hedge funds have recently bought and sold shares of the company. First Manhattan Co. raised its position in shares of Obseva by 38.2% in the 4th quarter. First Manhattan Co. now owns 2,117,112 shares of the company’s stock worth $26,802,000 after purchasing an additional 584,646 shares during the last quarter. Aisling Capital Management LP purchased a new position in Obseva in the 4th quarter worth about $17,551,000. Fosun International Ltd purchased a new position in Obseva in the 1st quarter worth about $2,494,000. Polar Capital LLP raised its position in Obseva by 16.7% in the 4th quarter. Polar Capital LLP now owns 175,000 shares of the company’s stock worth $2,216,000 after buying an additional 25,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Obseva by 92.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 135,547 shares of the company’s stock worth $1,734,000 after buying an additional 64,974 shares during the last quarter. 63.58% of the stock is owned by hedge funds and other institutional investors.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: How to Use a Moving Average for Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.